Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MT-4666 in mild to moderate Alzheimer's disease
NCT01764243Phase 2Completed
- Sponsor
- Mitsubishi Tanabe Pharma Corporation
- Start
- Nov 2012
- Primary completion
- Jun 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of encenicline in Alzheimer's disease (AD), sponsored by Mitsubishi Tanabe Pharma Corporation. Started Nov 2012; status: completed.
02
Drugs
encenicline
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT01764243.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01764243.